Literature DB >> 17395687

Best in class: a good principle for antibiotic usage to limit resistance development?

Sebastian G B Amyes1, Fiona M Walsh, John S Bradley.   

Abstract

The causes of antibiotic resistance are often complex and it is difficult to identify strategies to prevent or delay its emergence. One strategy has been to use less active members of a drug class, so that when resistance develops the more active members will still prevail. This strategy may often fail because this resistance may form the basis of resistance to the whole class. Often, less active drugs are the first to be discovered and more active versions follow, so we have had no choice; however, increasingly less active drugs are available to deal with specific infections and this may have a detrimental effect on the class as a whole.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17395687     DOI: 10.1093/jac/dkm059

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Evaluation of doripenem utilization and susceptibilities at a large urban hospital.

Authors:  Brett J Balderson; Mary E D Yates; Neelu P Patil; Katie J Suda
Journal:  Int J Clin Pharm       Date:  2011-10-08

2.  Molecular epidemiology of Escherichia coli sequence type 131 and its H30/H30-Rx subclones recovered from extra-intestinal infections: first report of OXA-48 producing ST131 clone from Iran.

Authors:  Z Hojabri; M Mirmohammadkhani; F Kamali; K Ghassemi; S Taghavipour; O Pajand
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-27       Impact factor: 3.267

Review 3.  Meropenem: a review of its use in the treatment of serious bacterial infections.

Authors:  Claudine M Baldwin; Katherine A Lyseng-Williamson; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  OXA β-lactamases.

Authors:  Benjamin A Evans; Sebastian G B Amyes
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

5.  Activity of Chitosans in combination with antibiotics in Pseudomonas aeruginosa.

Authors:  San Tin; Kishore R Sakharkar; Chu Sing Lim; Meena K Sakharkar
Journal:  Int J Biol Sci       Date:  2009-01-21       Impact factor: 6.580

6.  The characterization and antibiotic resistance profiles of clinical Escherichia coli O25b-B2-ST131 isolates in Kuwait.

Authors:  Ali A Dashti; Leila Vali; Sherief El-Shazly; Mehrez M Jadaon
Journal:  BMC Microbiol       Date:  2014-08-28       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.